BioSpace - Cytogen Corporation News, Search Jobs, Events

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

Cytogen Corporation

650 College Road East

Princeton New Jersey 08540 U.S.A.
Phone: 609-750-8200 Fax: 609-452-2476

Cytogen Corporation is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology. Currently marketed products include ProstaScintâ (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeedä I-125 and Pd-103 (two uniquely designed next generation radioactive seed implants for the treatment of localized prostate cancer), and Quadrametâ (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer). Cytogen is evolving a pipeline of oncology product candidates by developing its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences of Newtown, PA, a subsidiary of Cytogen Corporation, is engaged in the research and development of novel biopharmaceutical products using its portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information.

Last Updated: 10-16-02

Key Statistics

Email: cytoinfo@corpcomm.cytogen.com
Ownership:
Web Site: Cytogen Corporation
Employees: 70
Symbol: CYTO

Industry
Biotechnology

Segment
Human Diagnostics
Human Therapeutics

Collaborations
Advanced Magnetics, Inc. Marketing, licensing and supply agreement for Combidexâ and Code 7228, magnetic resonance imaging (MRI) contrast agents being developed for oncology applications
Dowpharma License to Quadramet
DRAXIS Health, Inc. Marketing, licensing and supply arrangement for BrachySeed iodine and palladium next-generation brachytherapy implants for the treatment of localized prostate cancer
Molecular Staging Inc. World-wide exclusive license for Rolling Circle Amplification Technology, or RCAT, to develop in vitro diagnostic tests using both PSMA and PSA
Northwest Biotherapeutics Development of ex vivo prostate cancer immunotherapy

Company News

EUSA Pharma Completes Acquisition Of Cytogen Corporation (CYTO) 5/9/2008 6:54:47 AM More...

Cytogen Corporation (CYTO) Reports First Quarter 2008 Financial Results 5/8/2008 8:57:38 AM More...

Cytogen Corporation (CYTO)'s Auditors Expressed Going-Concern Qualification 3/20/2008 8:43:53 AM More...

Cytogen Corporation (CYTO) Reports Fourth Quarter and Full Year 2007 Financial Results 3/14/2008 9:14:22 AM More...

Cytogen Corporation (CYTO) Says CEO Resigns; Names Replacement 11/12/2007 6:54:36 AM More...

Cytogen Corporation (CYTO) Reports Third Quarter 2007 Financial Results 11/7/2007 12:46:41 PM More...

Cytogen Corporation (CYTO) Retains ThinkEquity Partners to Assist in the Evaluation of Potential Strategic Alternatives 11/5/2007 11:16:35 AM More...

Cytogen Corporation (CYTO) to Present at the Biotechnology Industry Organization (BIO) Investor Forum 2007 10/3/2007 10:56:11 AM More...

Outcomes Data Demonstrating Prognostic Value of Cytogen Corporation (CYTO)'s PROSTASCINT Published in Peer-Reviewed Journal Urology 9/10/2007 11:52:49 AM More...

Cytogen Corporation (CYTO) to Present at Upcoming Investor Conferences in September 8/28/2007 2:39:29 PM More...

1